CN101137668B - 与可溶性G蛋白偶联受体（sGPCR）有关的组合物与方法 - Google Patents

与可溶性G蛋白偶联受体（sGPCR）有关的组合物与方法 Download PDF

Info

Publication number
CN101137668B
CN101137668B CN2006800078724A CN200680007872A CN101137668B CN 101137668 B CN101137668 B CN 101137668B CN 2006800078724 A CN2006800078724 A CN 2006800078724A CN 200680007872 A CN200680007872 A CN 200680007872A CN 101137668 B CN101137668 B CN 101137668B
Authority
CN
China
Prior art keywords
scrfr2α
nucleic acid
gpcr
protein
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800078724A
Other languages
English (en)
Chinese (zh)
Other versions
CN101137668A (zh
Inventor
A·陈
M·佩琳
W·维尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Development Foundation
Original Assignee
Research Development Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Development Foundation filed Critical Research Development Foundation
Publication of CN101137668A publication Critical patent/CN101137668A/zh
Application granted granted Critical
Publication of CN101137668B publication Critical patent/CN101137668B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
CN2006800078724A 2005-02-08 2006-02-08 与可溶性G蛋白偶联受体（sGPCR）有关的组合物与方法 Expired - Fee Related CN101137668B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65086605P 2005-02-08 2005-02-08
US60/650,866 2005-02-08
PCT/US2006/004321 WO2006086402A2 (en) 2005-02-08 2006-02-08 Compositions and methods related to soluble g-protein coupled receptors(sgpcrs)

Publications (2)

Publication Number Publication Date
CN101137668A CN101137668A (zh) 2008-03-05
CN101137668B true CN101137668B (zh) 2011-08-17

Family

ID=36793648

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800078724A Expired - Fee Related CN101137668B (zh) 2005-02-08 2006-02-08 与可溶性G蛋白偶联受体（sGPCR）有关的组合物与方法

Country Status (11)

Country Link
US (2) US7507794B2 (OSRAM)
EP (1) EP1885746B1 (OSRAM)
JP (1) JP4859248B2 (OSRAM)
KR (1) KR20070112155A (OSRAM)
CN (1) CN101137668B (OSRAM)
AT (1) ATE540970T1 (OSRAM)
AU (1) AU2006212813B2 (OSRAM)
CA (1) CA2597065C (OSRAM)
DK (1) DK1885746T3 (OSRAM)
RU (1) RU2423378C2 (OSRAM)
WO (1) WO2006086402A2 (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007090087A2 (en) * 2006-01-27 2007-08-09 Research Development Foundation Use of corticotropin releasing factor receptor-2 inhibitors for treating insulin-related diseases
WO2009046874A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Therapeutic combination of trh-potentiating peptide and stresscopin
AU2008297885A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of GLP-1 as a therapeutic agent
WO2009040027A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of the peptide stresscopin as a therapeutic agent
AU2008303941A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of the peptide Pro-Gly-Thr-Cys-Glu-Ile-Cys-Ala-Tyr-Ala-Ala-Cys-Thr-Gly-Cys as a therapeutic agent
WO2011025905A1 (en) 2009-08-28 2011-03-03 Research Development Foundation Urocortin 2 analogs and uses thereof
WO2011062935A1 (en) * 2009-11-17 2011-05-26 The Regents Of The University Of California Compositions and assay systems for intracellular processes
US9981017B2 (en) 2010-04-02 2018-05-29 Hanmi Science Co., Ltd. Insulin conjugate using an immunoglobulin fragment
AR081066A1 (es) * 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
AU2012220558A1 (en) * 2011-02-23 2013-08-22 Massachusetts Institute Of Technology Water soluble membrane proteins and methods for the preparation and use thereof
PT2814513T (pt) * 2012-02-14 2018-03-02 Univ California Entrega sistémica e expressão regulada de genes parácrinos para doenças cardiovasculares e outras doenças
JOP20170153A1 (ar) 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
WO2018132768A1 (en) * 2017-01-13 2018-07-19 Sanna Pietro P Methods and compositions for treating hpa hyperactivity
WO2018136856A1 (en) 2017-01-23 2018-07-26 Massachusetts Institute Of Technology Multiplexed signal amplified fish via splinted ligation amplification and sequencing
WO2018157074A1 (en) 2017-02-24 2018-08-30 Massachusetts Institute Of Technology Methods for diagnosing neoplastic lesions
WO2018157048A1 (en) 2017-02-24 2018-08-30 Massachusetts Institute Of Technology Methods for examining podocyte foot processes in human renal samples using conventional optical microscopy
WO2019023214A1 (en) 2017-07-25 2019-01-31 Massachusetts Institute Of Technology ATAC IN SITU SEQUENCING
WO2019046699A1 (en) * 2017-09-01 2019-03-07 Massachustetts Institute Of Technology NON-DETERGENT GPCR BIOELECTRONIC INTERFACES COUPLED TO THE 2D S-PROTEIN NETWORK, DEVICES AND METHODS OF USE THEREOF
US11173992B2 (en) 2017-12-28 2021-11-16 Legionarus, Llc Buoyancy garment
US11873374B2 (en) 2018-02-06 2024-01-16 Massachusetts Institute Of Technology Swellable and structurally homogenous hydrogels and methods of use thereof
WO2020013833A1 (en) 2018-07-13 2020-01-16 Massachusetts Institute Of Technology Dimethylacrylamide (dmaa) hydrogel for expansion microscopy (exm)
US11471112B2 (en) 2018-11-21 2022-10-18 Legionarius, Llc Mobile application for wearable device
US12478324B2 (en) 2019-02-20 2025-11-25 Legionarius, Llc Sensors for wearable devices
USD905935S1 (en) 2019-02-20 2020-12-29 Legionarius, Llc Shirt with back pocket
WO2020172247A1 (en) 2019-02-22 2020-08-27 Massachusetts Institute Of Technology Iterative direct expansion microscopy
US12265004B2 (en) 2019-11-05 2025-04-01 Massachusetts Institute Of Technology Membrane probes for expansion microscopy
WO2021113505A1 (en) 2019-12-05 2021-06-10 Massachusetts Institute Of Technology Method for preparing a specimen for expansion microscopy
WO2026021448A1 (zh) * 2024-07-22 2026-01-29 健达九州(北京)生物科技有限公司 一种M4Di变体以及其治疗癫痫的应用
CN121177454A (zh) * 2025-09-05 2025-12-23 南通大学 Gip受体激动剂在促进毛发再生中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4883750A (en) 1984-12-13 1989-11-28 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5063245A (en) 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5786203A (en) * 1994-06-14 1998-07-28 Neurocrine Biosciences, Inc. Isolated nucleic acid encoding corticotropin-releasing factor2 receptors
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
CA2375943A1 (en) * 1999-07-15 2001-01-25 Research Development Foundation Corticotropin releasing factor receptor 2 deficient mice and uses thereof
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
CA2576435A1 (en) 2004-08-09 2006-03-23 Research Development Foundation Determination of the 3d-structure of an extracellular domain of a b1 g-protein coupled receptor by nmr analysis

Also Published As

Publication number Publication date
KR20070112155A (ko) 2007-11-22
ATE540970T1 (de) 2012-01-15
CA2597065C (en) 2014-10-14
JP4859248B2 (ja) 2012-01-25
AU2006212813A1 (en) 2006-08-17
WO2006086402A3 (en) 2006-12-14
DK1885746T3 (da) 2012-03-26
CA2597065A1 (en) 2006-08-17
JP2008529500A (ja) 2008-08-07
US20070042954A1 (en) 2007-02-22
RU2423378C2 (ru) 2011-07-10
EP1885746B1 (en) 2012-01-11
US20090117649A1 (en) 2009-05-07
RU2007133648A (ru) 2009-03-20
WO2006086402A2 (en) 2006-08-17
EP1885746A2 (en) 2008-02-13
AU2006212813B2 (en) 2012-02-02
US7507794B2 (en) 2009-03-24
CN101137668A (zh) 2008-03-05
US8258279B2 (en) 2012-09-04

Similar Documents

Publication Publication Date Title
CN101137668A (zh) 与可溶性G蛋白偶联受体（sGPCR）有关的组合物与方法
JP5887441B2 (ja) Ｒａｇｅ融合タンパク質
RU2697762C2 (ru) Композиции, применения и способы лечения нарушений и заболеваний обмена веществ
Czura et al. Targeting high mobility group box 1 as a late-acting mediator of inflammation
CN107921085B (zh) 用于治疗衰老相关病症的方法和组合物
AU631112B2 (en) Treatment of type 2 diabetes mellitus
KR102692516B1 (ko) 융합 단백질을 포함하는 간염증, 간섬유화 및 간경화 예방 또는 치료용 약학적 조성물
US8333969B2 (en) Use of immunesuppressant receptor
JP2021185178A (ja) 胆汁酸に関係した障害の治療方法
JP2001509373A (ja) 単純ヘルペスウイルス侵入メディエーターのためのリガンドおよびその使用方法
US6238915B1 (en) Mutant human growth hormones and their uses
JP2021513969A (ja) Ｔｒｅｍまたはｔｒｅｍｌタンパク質を調節するための組成物および使用方法
JP2018529729A (ja) 胆汁酸障害の処置
CN102448990A (zh) 腺苷酸环化酶相关蛋白(cap1)及其作为免疫调节靶标的应用
EA012567B1 (ru) Нуклеиновая кислота, кодирующая il-32, белок il-32, антитело к il-32 и способы применения белка и антитела
CA2507373A1 (en) Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases
Volpina et al. A fragment of the receptor for advanced glycation end products restores the spatial memory of animals in a model of Alzheimer’s disease
JPH10501888A (ja) 自己免疫疾患、とくに多発性硬化症の診断および治療における使用のためのアルファｂクリスタリン
Kotani et al. Identification of thyroiditogenic epitope on porcine thyroid peroxidase for C57BL/6 mice
EA006744B1 (ru) Применение ингибиторов il-18 для лечения и предотвращения повреждений цнс
WO2015038891A2 (en) Functional peptide analogs of pedf
CA2516364A1 (en) Method of modulation
JPH1175866A (ja) マウスＦｒｉｚｚｌｅｄ−６ 遺伝子に類似したヒト７ＴＭ受容体
WO2003086457A2 (en) Method of treating or preventing autoimmune disease
HK1247102B (zh) 用於治疗衰老相关病症的方法和组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110817

Termination date: 20200208